For individuals battling Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the emergence of Vyndamax and Attruby represents a true breakthrough . These novel therapies protect the transthyretin protein, preventing its harmful build-up and reducing the severity of the diseas